Monopar Therapeutics Files 8-K Current Report
Ticker: MNPR · Form: 8-K · Filed: Feb 27, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Feb 27, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, disclosure
TL;DR
**Monopar Therapeutics filed an 8-K on Feb 27, but the specific event details are missing from this excerpt.**
AI Summary
Monopar Therapeutics Inc. filed an 8-K Current Report on February 27, 2024, disclosing Regulation FD information and Financial Statements and Exhibits. The specific details of these disclosures, including any particular names, dollar amounts, or the nature of the events, are not provided in this filing excerpt.
Why It Matters
This filing indicates Monopar Therapeutics is making a public disclosure, which could contain material information for investors. However, the real-world impact cannot be assessed without the actual content of the Regulation FD disclosure or the financial statements.
Risk Assessment
Risk Level: medium — The filing itself is a standard regulatory disclosure; without the content of the reported events, no specific financial or operational risk can be assessed.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — registrant
- Delaware (company) — state of incorporation
- 001-39070 (dollar_amount) — SEC File Number
- February 27, 2024 (date) — date of earliest event reported
FAQ
What type of SEC filing is this document?
This document is an 8-K Current Report, filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Who is the registrant named in this filing?
The registrant is MONOPAR THERAPEUTICS INC.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is February 27, 2024.
What specific items are mentioned as being disclosed in this 8-K?
The filing indicates 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' as item information.
What is the business address of Monopar Therapeutics Inc.?
The business address of Monopar Therapeutics Inc. is 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-02-27 06:59:57
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20240226_8k.htm (8-K) — 25KB
- ex_630799.htm (EX-99.1) — 11KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-005624.txt ( ) — 177KB
- mnpr-20240227.xsd (EX-101.SCH) — 3KB
- mnpr-20240227_def.xml (EX-101.DEF) — 12KB
- mnpr-20240227_lab.xml (EX-101.LAB) — 15KB
- mnpr-20240227_pre.xml (EX-101.PRE) — 12KB
- mnpr20240226_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On February 27, 2024, Monopar Therapeutics Inc. issued a press release announcing the internationally recognized radiopharmaceutical physician, Professor Rodney Hicks, will be the lead investigator for Monopar's MNPR-101-Zr Phase 1 dosimetry clinical trial in advanced cancer patients. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated February 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: February 27, 2024 By: /s/ Kim R. Tsuchimoto Name: Kim R. Tsuchimoto Title: Chief Financial Officer and Director